MURA insider transaction filings
Mural Oncology plc — 24 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-12-05. Screen MURA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-12-05 | 4 | Loew Caroline — Chief Executive Officer, Director | Disposition to issuer (D): 293,059 · Disposition to issuer (D): 379,690 (derivative) · Disposition to issuer (D): 90,025 (derivative) · Disposition to issuer (D): 134,225 (derivative) | EDGAR |
| 2025-12-05 | 4 | Goodman Vicki L — Chief Medical Officer | Disposition to issuer (D): 84,727 · Disposition to issuer (D): 135,604 (derivative) · Disposition to issuer (D): 65,000 (derivative) | EDGAR |
| 2025-12-05 | 4 | Minegishi Sachiyo — Director | Disposition to issuer (D): 8,637 (derivative) · Disposition to issuer (D): 15,335 (derivative) | EDGAR |
| 2025-12-05 | 4 | Hickey Benjamin — Director | Disposition to issuer (D): 8,637 (derivative) · Disposition to issuer (D): 8,462 (derivative) · Disposition to issuer (D): 15,021 (derivative) | EDGAR |
| 2025-12-05 | 4 | Cutler Adam D. — Chief Financial Officer | Disposition to issuer (D): 99,290 · Disposition to issuer (D): 146,452 (derivative) · Disposition to issuer (D): 65,000 (derivative) | EDGAR |
| 2025-12-05 | 4 | Keson-Brookes Maiken — Chief Legal Officer | Disposition to issuer (D): 68,834 · Disposition to issuer (D): 54,242 (derivative) · Disposition to issuer (D): 31,200 (derivative) · Disposition to issuer (D): 65,000 (derivative) | EDGAR |
| 2025-12-05 | 4 | Golumbeski George — Director | Disposition to issuer (D): 8,637 (derivative) · Disposition to issuer (D): 15,334 (derivative) | EDGAR |
| 2025-12-05 | 4 | Jackson Scott Thomas — Director | Disposition to issuer (D): 8,637 (derivative) · Disposition to issuer (D): 8,462 (derivative) · Disposition to issuer (D): 15,021 (derivative) | EDGAR |
| 2025-12-05 | 4 | Cuss Francis M — Director | Disposition to issuer (D): 8,637 (derivative) · Disposition to issuer (D): 8,462 (derivative) · Disposition to issuer (D): 15,021 (derivative) | EDGAR |
| 2025-11-10 | 4 | Goodman Vicki L — Chief Medical Officer | Sale (S): 5,036 @ $2.08 | EDGAR |
| 2025-11-10 | 4 | Cutler Adam D. — Chief Financial Officer | Sale (S): 7,148 @ $2.09 | EDGAR |
| 2025-07-23 | 4 | Keson-Brookes Maiken — See Remarks | Sale (S): 2,572 @ $2.48 | EDGAR |
| 2025-07-22 | 4 | Keson-Brookes Maiken — See Remarks | Sale (S): 2,158 @ $2.48 | EDGAR |
| 2025-07-09 | 4 | Loew Caroline — Chief Executive Officer, Director | Sale (S): 12,531 @ $2.43 | EDGAR |
| 2025-06-13 | 4 | Minegishi Sachiyo — Director | Grant/award (A): 8,637 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Hickey Benjamin — Director | Grant/award (A): 8,637 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Golumbeski George — Director | Grant/award (A): 8,637 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Jackson Scott Thomas — Director | Grant/award (A): 8,637 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Cuss Francis M — Director | Grant/award (A): 8,637 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Loew Caroline — Chief Executive Officer, Director | Grant/award (A): 72,275 @ $0 · Sale (S): 4,313 @ $3.36 · Grant/award (A): 134,225 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Goodman Vicki L — Chief Medical Officer | Grant/award (A): 35,000 @ $0 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Cutler Adam D. — Chief Financial Officer | Grant/award (A): 35,000 @ $0 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Keson-Brookes Maiken — See Remarks | Grant/award (A): 35,000 @ $0 · Sale (S): 1,262 @ $3.36 · Sale (S): 1,469 @ $3.45 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-02-25 | 4 | Goodman Vicki L — Chief Medical Officer | Sale (S): 13,186 @ $3.89 | EDGAR |
Recent 8-K events — Mural Oncology plc
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-12-05 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-24 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2025-08-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-04-15 | 8-K | ? 8.01 — Other Events | EDGAR |
| 2025-03-25 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-03-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-11 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MURA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →